"The study was published in Lancet on hydroxychloroquine and chloroquine and its effect on COVID-19.
It is an observational study with statical parameters and analysis which is not sufficiently good.
In our letter to the Lancet editor, we have written that the study design and statical interferences are not right therefore study does not deserve any attention of the readers.
We believe that WHO's decision to temporarily halt the trials is not correct and demanded that the clinical trials of hydroxychloroquine for its use in COVID-19 cases must resume as early as possible," said Mande after WHO halts clinical trials of hydroxychloroquine for COVID-19.
Mohan Bhagwat, Sarsanghchalak of the Rashtriya Swayamsevak Sangh (RSS), spoke on the ongoing tension with China along the Line of Actual Control (LAC) in Ladakh. He said that India's response had subdued the neighbouring nation and dealt it a blow. He made the comments during his annual Dussehra address. He also performed 'shastra puja' or worship of weapons reportedly at the Maharshi Vyas auditorium in Maharashtra's Nagpur. Only 50 participants were allowed inside the venue due to the Covid-19 pandemic, as per reports. Watch the full video for more.
Credit: HT Digital Content Duration: 03:39Published
Union Health Minister Dr Harsh Vardhan chaired meeting with Department of Science and Technology, and Council of Scientific and Industrial Research on COVID-19 appropriate behaviour, through video conferencing.
While addressing at the 79th Foundation Day of Council of Scientific and Industrial Research (CSIR) in the national capital on September 26, Health Minister Dr Harsh Vardhan spoke on COVID-19 pandemic. He said, "Now we have 110 Personal Protective Equipment (PPE) manufacturers in India, producing over 5 lakh per day." "States who used to cry about not getting adequate number of PPEs, now say they don't have place to keep them when we talk about sending PPEs," Health and Family Welfare Minister added.
Council of Scientific and Industrial Research on September 20 informed that Drugs Controller General of India has approved CSIR's paper-based testing kit called Feluda for COVID-19. CSIR, Director General S Mande said, "Our Delhi CSIR lab's been working on studying CRISPR-Cas immunity. They have experience of working in this particular area before COVID-19 and could repurpose the thing for COVID and developed a paper-based testing kit called Feluda and got formal approval from DCGA. Mande further explained the functioning of the paper based test. "It's different as RTPCR detects RNA and amplifies it using a polymerase chain reaction that is costly. This paper-based test also detects RNA but by a CRISPR guided system. The paper lights up if there is any virus RNA to show a sample is positive, in 45 minutes," he added.
The virus most often behind the common cold is capable of preventing the flu virus. It prevents the flu from infecting airways by jump-starting the body's immune defenses. A study published Friday by The Lancet Microbe found this evidence recently. They did an analysis of more than 13,000 patients with symptoms of a respiratory infection. Those who had rhinovirus were not simultaneously infected with the flu virus.
Credit: Wochit News Duration: 00:36Published
Tweets about this
Lermont RT @Lermont: The NIH needs to resume clinical trials for #HCQ immediately!
Their June decision to halt them was based on faulty studies.
Ov… 4 days ago
Lermont The NIH needs to resume clinical trials for #HCQ immediately!
Their June decision to halt them was based on faulty… https://t.co/x9vJRMzdba 4 days ago
Council of Scientific and Industrial Research (CSIR), Director General Shekhar Mande said that WHO decision to halt trials of hydroxychloroquine for COVID-19 is not correct and it must resume as early..
Credit: HT Digital Content Duration: 03:14Published
While commenting on World Health Organisation's decision to temporarily suspend clinical trials of hydroxychloroquine, Director General of Council of Scientific and Industrial Research (CSIR), Shekhar..